Search results for "Azoles"

showing 10 items of 899 documents

Associations Among Psychologically Controlling Parenting, Autonomy, Relatedness, and Problem Behaviors During Emerging Adulthood.

2017

ABSTRACTThe present study aimed to investigate the relations among perceived parental psychological control (PPC), autonomy and relatedness, and negative outcomes during emerging adulthood in two cultural contexts: Italy and the USA. More specifically, we explored the mechanisms through which dependency-oriented PPC (DPPC) and achievement-oriented PPC (APPC) are associated with both internalizing and externalizing difficulties, focusing on the mediating role of autonomy and relatedness. Participants were 418 European-American and 359 Italian college students. Results indicated that the expressions of PPC with regard to dependency and achievement were related to emerging adults’ negative out…

AdultCross-Cultural ComparisonMaleParentsPsychology (all)genetic structuresAdolescent3304media_common.quotation_subjectCodependency PsychologicalEthnic groupPsychological intervention050109 social psychologyPersonal autonomyEducationDevelopmental psychologySettore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneYoung AdultPsychological controlHumansBusiness0501 psychology and cognitive sciencesYoung adultParent-Child RelationsGeneral Psychologymedia_commonCross-cultural differenceParentingdevelopmental issues05 social sciencesSettore M-PSI/03 - PsicometriaCross-cultural differences; developmental issues; parenting; 3304; Business Management and Accounting (miscellaneous); Psychology (all)developmental issueCross-cultural studiesUnited StatesCross-cultural differencesThiazolesPersonal AutonomyBusiness Management and Accounting (miscellaneous)FemaleManagement and Accounting (miscellaneous)PsychologyAutonomy050104 developmental & child psychologyClinical psychologyThe Journal of psychology
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease

2007

Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infections in recipients of hematopoietic stem cell transplants (HSCTs) who have graft-versus-host disease (GVHD). Design. Pharmacokinetic analysis in a subset of posaconazole-treated patients from a large, multicenter, phase III, randomized, double-blind, double-dummy, parallel-group trial that compared posaconazole with fluconazole. Setting. Ninety international medical centers. Patients. The subset of patients comprised 246 HSCT recipients for whom pharmacokinetic data were available. Intervention. All patients received posaconazole 200 mg oral suspension 3 times/day for a max…

AdultDiarrheaMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsAdolescentCmaxGraft vs Host DiseaseOpportunistic InfectionsGastroenterologySex FactorsDouble-Blind MethodPharmacokineticsOral administrationInternal medicinemedicineHumansTransplantation HomologousPharmacology (medical)MycosisAgedbusiness.industryBody WeightRacial GroupsAge FactorsHematopoietic Stem Cell TransplantationMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesAcute DiseaseChronic DiseaseFemalebusinessFluconazolemedicine.drugPharmacotherapy
researchProduct

Treatment of Vaginal Trichomoniasis with a Single Dose of Tinidazole

1974

SummaryTwenty-two patients with proven vaginal trichomoniasis were treated with a single dose of 2 g. tinidazole. Twenty-one patients were cured, at both the early and the late follow-up visits. No side-effects were noted and no abnormalities of the clinical laboratory parameters were found in the trial. A historical comparison with published works was carried out and the results compared favourably with those found in the literature for tinidazole as well as for other agents used in a similar fashion.

AdultGynecologymedicine.medical_specialtyDose-Response Relationship Drugbusiness.industryVaginal trichomoniasisAdministration OralAntitrichomonal AgentsGeneral MedicineMiddle AgedTrichomonal VaginitisDermatologyTinidazoleAntitrichomonal agentchemistry.chemical_compoundchemistryNitroimidazolesmedicineHumansFemaleTrichomonas Vaginitisbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment

2009

A novel cancer stem-like cell line (3AB-OS), expressing a number of pluripotent stem cell markers, was irreversibly selected from human osteosarcoma MG-63 cells by long-term treatment (100 days) with 3-aminobenzamide (3AB). 3AB-OS cells are a heterogeneous and stable cell population composed by three types of fibroblastoid cells, spindle-shaped, polygonal-shaped, and rounded-shaped. With respect to MG-63 cells, 3AB-OS cells are extremely smaller, possess a much greater capacity to form spheres, a stronger self-renewal ability and much higher levels of cell cycle markers which account for G1-S/G2-M phases progression. Differently from MG-63 cells, 3AB-OS cells can be reseeded unlimitedly wit…

AdultHomeobox protein NANOGAdolescentPhysiologyCellular differentiationClinical BiochemistryApoptosisBiologyStem cell markerYoung Adultcancer stemm cells osteosarcoma PARP inhibitorsCancer stem cellCell Line TumorSettore BIO/10 - BiochimicaHumansRhodamine 123Enzyme InhibitorsProgenitor cellChildInduced pluripotent stem cellCell ShapeCell potencyFluorescent DyesOsteosarcomaCell DifferentiationCell BiologyCalcium Channel BlockersDrug Resistance MultipleGene Expression Regulation NeoplasticVerapamilBenzamidesImmunologyNeoplastic Stem CellsCancer researchATP-Binding Cassette TransportersBenzimidazolesStem cellBiomarkersJournal of Cellular Physiology
researchProduct

Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

2021

Abstract Aims Lomitapide is a lipid-lowering agent indicated as an adjunct therapy for adult homozygous familial hypercholesterolaemia (HoFH). This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Europe. Methods and results In a multicentre retrospective, observational study including 75 HoFH patients treated with lomitapide in a real-world clinical setting from 9 European countries, low-density lipoprotein cholesterol (LDL-C) changes, adverse events (AEs), and major adverse cardiovascular events (MACE) were assessed. After a median 19 months (interquartile range 11–41 months) of treatment with a mean dosage of 20 mg of lomitapide…

AdultHomozygous Familial HypercholesterolemiaSettore MED/09 - Medicina InternaEpidemiologyAnticholesteremic AgentsHomozygoteMedium-term efficacyCholesterol LDLMedium-term safetyBenzimidazoleLomitapideHomozygous Familial Hypercholesterolemia; atherosclerosis; lomitapide; medium-term efficacy; medium-term safetyHyperlipoproteinemia Type IIHomozygous familial hypercholesterolaemiaRetrospective StudieAtherosclerosiAnticholesteremic AgentHumansBenzimidazolesatherosclerosisCardiology and Cardiovascular MedicineRetrospective StudiesHuman
researchProduct

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

2019

 The urgent need in HCV-infected patients with liver disease mandated the rapid implementation of IFN-free DAA combination therapies following their regulatory approval in 2014 and 2015 without full knowledge of the optimal combinations and regimens. Investigating the evolution of the DAA utilization patterns and treatment outcomes could provide learnings for future situations. This was an analysis of a prospective observational database from the German Hepatitis C Registry (DHC-R) covering a period from May 2014 to September 2015. Adult patients had evidence of chronic HCV GT1 or GT4 infection and were treated with an IFN-free combination regimen of simeprevir (SMV) + sofosbuvir (SOF) or o…

AdultLedipasvirSimeprevirmedicine.medical_specialtyDaclatasvirSustained Virologic ResponseSofosbuvirHepacivirusAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineHumansMedicineProspective StudiesRegistries030212 general & internal medicineFluorenesDasabuvirbusiness.industryGastroenterologyHepatitis C ChronicHepatitis COmbitasvirDrug CombinationsRegimenTreatment OutcomechemistryParitaprevirBenzimidazolesDrug Therapy Combination030211 gastroenterology & hepatologySofosbuvirbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Leptin and leptin receptor expression in asthma.

2009

Background The adipokine leptin is a potential new mediator for bronchial epithelial homeostasis. Asthma is a chronic inflammatory disease characterized by airway remodeling that might affect disease chronicity and severity. TGF-β is a tissue growth factor the dysregulation of which is associated with airway remodeling. Objective We sought to determine whether a bronchial epithelial dysfunction of the leptin/leptin receptor pathway contributes to asthma pathogenesis and severity. Methods We investigated in vitro the presence of leptin/leptin receptor on human bronchial epithelial cells. Then we studied the effect of TGF-β and fluticasone propionate on leptin receptor expression. Finally, th…

AdultLeptinMalemedicine.medical_specialtyPyridinesMorpholinesImmunologyAdipokineBronchiRespiratory MucosaSettore MED/10 - Malattie Dell'Apparato RespiratorioSettore BIO/09 - FisiologiaCell LinePathogenesisTransforming Growth Factor beta1Leptin leptin receptor severe asthma epithelium TGF-b remodelingInternal medicineImmunology and AllergyMedicineHumansEnzyme InhibitorsReceptorCell ProliferationLeptin receptorbusiness.industryTumor Necrosis Factor-alphaLeptindigestive oral and skin physiologyImidazolesMiddle AgedEpitheliumAsthmaRecombinant Proteinsrespiratory tract diseasesAndrostadienesmedicine.anatomical_structureEndocrinologyChromonesImmunologyFluticasoneReceptors LeptinFemalebusinesshormones hormone substitutes and hormone antagonistsEx vivoTransforming growth factorThe Journal of allergy and clinical immunology
researchProduct

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

2015

ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

AdultLiver CirrhosisMaleDaclatasvirPyrrolidinesAlpha interferonHIV InfectionsHepacivirusPharmacologyAntiviral AgentsRaltegravir PotassiumPolyethylene Glycolschemistry.chemical_compoundPharmacokineticsRaltegravir PotassiumRibavirinMedicineHumansPharmacology (medical)PharmacologySulfonamidesbusiness.industryCoinfectionRibavirinImidazolesvirus diseasesInterferon-alphaValineHepatitis CHepatitis C ChronicMiddle AgedRaltegravirmedicine.diseaseIsoquinolinesdigestive system diseasesRecombinant ProteinsInfectious DiseaseschemistryLiverHIV-1AsunaprevirDrug Therapy CombinationFemaleCarbamatesbusinessmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractor…

2018

AbstractPurpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested.Results:The study included 187 patients. The most common treatment-related adverse events were…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyAdministration OralAntineoplastic AgentsDrug resistanceGastroenterologyYoung Adult03 medical and health sciencesHyperphosphatemia0302 clinical medicineRefractoryErdafitinibNeoplasmsQuinoxalinesInternal medicinemedicineHumansNeoplasmDosingAdverse effectProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overbusiness.industryGenetic VariationMiddle AgedPrognosismedicine.diseaseReceptors Fibroblast Growth FactorTreatment Outcome030104 developmental biologyOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisRetreatmentPyrazolesFemalebusinessClinical Cancer Research
researchProduct